Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The [Personalis NeXT Platform](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.personalis.com%2Fimmunoid- next-platform%2F&esheet=52534858&newsitemid=20211118006333&lan=en- US&anchor=Personalis+NeXT+Platform&index=2&md5=994af974cf5c973f890d0bc5a72ef63b)® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' [Clinical Laboratory](https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.personalis.com%2Fabout%2Flaboratory%2F&esheet=52534858&newsitemid=20211118006333&lan=en- US&anchor=Clinical+Laboratory&index=3&md5=214191f02a8e211e8a6037256ce4a478) was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists- accredited.
Education & Experience :
_Personalis is an Equal Opportunity Employer/Minorities/Females/Veterans/Disabilities. Personalis offers a competitive compensation package. _